MorphoSys AG (XSWX:MOR) Receivables Turnover : 1.84 (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MorphoSys AG's Revenue for the three months ended in Dec. 2023 was CHF55.7 Mil. MorphoSys AG's average Accounts Receivable for the three months ended in Dec. 2023 was CHF30.3 Mil. Hence, MorphoSys AG's Receivables Turnover for the three months ended in Dec. 2023 was 1.84.

MorphoSys AG Receivables Turnover Historical Data

The historical data trend for MorphoSys AG's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Receivables Turnover Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

4.30

6.65

2.21

3.25

3.74

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															0.90	0.81	0.79	0.88	1.84

Competitive Comparison of MorphoSys AG's Receivables Turnover

For the Biotechnology subindustry, MorphoSys AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Receivables Turnover falls into.

MorphoSys AG Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

MorphoSys AG's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	224.714	/ (	(90.033	+	30.267)	/	2 )
=	224.714	/	60.15
=	3.74

MorphoSys AG's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	55.715	/ (	(0	+	30.267)	/	1 )
=	55.715	/	30.267
=	1.84

MorphoSys AG (XSWX:MOR) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

MorphoSys AG Receivables Turnover Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.